J&J, Amgen Scrutinized For Anemia Drug Marketing

Law360, New York (April 2, 2008, 12:00 AM EDT) -- Congressional leaders have asked Johnson & Johnson and Amgen Inc. to turn over records related to the advertising and marketing of their anemia drugs amid reports of increased risks of blood clots and death when used in high doses.

Rep. John Dingell (D-Mich.), the chairman of the House Energy and Commerce Committee, and Rep. Bart Stupak (D-Mich.), chairman of the subcommittee of Oversight and Investigations, said in letters dated Tuesday that they were concerned with the ways the companies marketed the treatments, Procrit, Aranesp and Epogen,...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.